



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

Date: 9/13/04

By: [Signature]  
Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)
Martin Dugas, et al.	) EXAMINER: Unassigned
SERIAL NO.: 10/575,635	) ART UNIT: Unassigned
PCT FILING DATE: NOVEMBER 4, 2004	) Confirmation No. N/A
FOR: <u>METHOD FOR DISTINGUISHING</u> <u>LEUKEMIA SUBTYPES</u>	) DOCKET NO 22331-US

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.


Applicants wish to provide the USPTO with an electronic copy of WO 03/039433A2, which is in excess of 2,900 pages.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.


Respectfully submitted,

Date: 9/12/06

  
Robert W. Mann  
Reg. No. 48,555

Correspondence Address:  
Roche Molecular Systems, Inc  
1145 Atlantic Avenue  
Alameda, CA 94501  
Tele: (510) 814-2800  
Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 22331-US	Serial No. 10/575,635
<b>LIST OF INFORMATION CITED BY APPLICANT</b> (Use separate sheets if necessary)	Applicants: Martin Dugas, et al.	
	International Filing Date: Nov 4, 2004	Group: N/A



### U.S. PATENT DOCUMENTS

* EXAMINER'S INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
	2	5,445,934	08/29/95	Fodor, et al	435	6	09/30/92
	3	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
	4	5,700,637	12/23/97	E. Southern	435	6	04/19/94
	5	5,744,305	04/28/98	Fodor, et al	435	6	06/06/95
	6	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
	7	5,945,334	08/31/99	Besemer, et al	435	287.2	06/07/95
	8	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
	9	2003/0138793 A1	07/24/03	Su, et al	435	6	06/10/02

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	10	0 373 203 B1	08/31/94	EP			
	11	0 619 321 B1	01/07/90	EP			
	12	1 043 676 A1	10/11/00	EP			
	13	WO 92/02638	02/20/92	PCT			
	14	WO 03/039443 A2	05/15/03	PCT			
	15	WO 2005/043161 A3	05/12/05	PCT			
	16	EP2004/012463 Search Report	06/09/05	PCT			

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	17	Alizadeh, A., et al., 1999, "The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes", Cold Springs Harbor Symposium on Quantitative Biology, Volume LXIV, Cold Springs Harbor Laboratory Press, pp 71-78
	18	Brown, M., et al, 2000, "Knowledge-based analysis of microarray gene expression data by using support vector machines, PNAS, 97(1):262-267
	19	Dugas, M., et al., 2001, "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping", Leukemia, 15:1805-1810
	20	Dugas, M., et al., 2002, "Impact of Integrating Clinical and Genetic Information", In Silico Biology, 2:383-391
	21	Furey, T., et al., 2000, "Support vector machine classification and validation of cancer tissue samples using microarray expression data", Bioinformatics, 16(10):906-914
	22	Gieselmann, V., et al, 1994, "Molecular Genetics of Metachromatic Leukodystrophy", Human Mutation, 4:233-242
	23	Golub, T., et al, 1999, "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 286:531-537

24	Haferlach, T., et al., "Abstract: The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", <i>Blood</i> , 100, Abstract 523
25	Harlow, E., et al, 1988, "Antibodies A Laboratory Manual", <i>Cold Spring Harbor Laboratory</i>
26	Kern, W., et al., 2002, "Abstract: Expression Pattern of Apoptosis-Related Genes in Acute Myeloid Leukemia with Complex Aberrant Karyotype", <i>Blood</i> , 100, Abstract 1236
27	Koehler, G., et al., 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", <i>Nature</i> . 256:495-497
28	Kohlmann, A., et al., 2002, "Abstract: A Simplified and Partially Automated target Preparation Method for Gene Expression Profiling", <i>Blood</i> , 100, Abstract 4287
29	Kohlmann, A., et al., 2002, "Abstract:: A Gene Expression Study of 59 Acute Myeloid Leukemia (AML) Patients with recurrent Cytogenetic Abnormalities", <i>Blood</i> , 100, Abstract 1205
30	Kohlmann, A., et al., 2002, "Abstract: Gene Expression Profiles of t(11q23)/MLL Positive ALL and AML", <i>Blood</i> , 100(11): Abstract No. 30.
31	Kohlmann, A., et al., 2003, "Molecular Characterization of Acute Leukemias by Use of Microarray Technology", <i>Genes, Chromosomes &amp; Cancer</i> , 37:396-405
32	Liu, G., et al., 2003, "NetAffx: Affymetrix probesets and annotations", <i>Nucleic Acids Research</i> , 31(1):82-86
33	Sambrook, J., et al., 1989, "Molecular Cloning A Laboratory Manual Second Edition", <i>Cold Spring harbor Laboratory Press</i> ,
34	Schoch, C., et al., 2002, "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", <i>PNAS</i> , 99(15):10008-10013
35	Schoch, C., et al., 2001, "AML with recurring chromosome abnormalities as defined in the new WHO-Classifications: Incidence of subtypes, additional genetic abnormalities, FAB subtype and age distribution in an unselected series of 1897 cytogenetically and moleculargenetically analyzed AML", <i>Blood</i> , 98(11 part 1):457a-458a
36	Schoch, C., et al., 2002, "Abstract: AML with complex Aberrant Karyotype can be distinguished from all other AML subtypes by gene expression profiles and are characterized by higher expression of genes involved in DNA repair", <i>Blood</i> , 100, Abstract No. 1204
37	Storey, J., et al., 2003, "Statistical significance for genomewide studies," <i>PNAS</i> , 100(16):9440-9445
38	Tipping, A., et al., 2003, "Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to innately mesylate," <i>Experimental Hematology</i> , 31:1073-1080

EXAMINER

DATE CONSIDERED

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.